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Caspase-9 and APAF-1 form
an active holoenzyme
Joe Rodriguez 1,2 and Yuri Lazebnik 1,3
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New
York 11724 USA; 2Molecular and Cell Biology Graduate
Program, State University of New York at Stony Brook,
Stony Brook, New York 11733 USA
Autocatalytic activation of initiator caspases is the link
between pro-apoptotic signals and the destruction ma-
chinery of apoptosis. Activation of caspase-9, which me-
diates oncogene and drug-induced apoptosis, requires
binding to the protein APAF-1. We found that the pro-
teolytic activity of caspase-9 in a complex with APAF-1
is several orders of magnitude higher than that of the free
enzyme. Thus, this complex functions as a holoenzyme
in which caspase-9 is the catalytic subunit and APAF-1
its allosteric regulator. We argue that caspase-9 is acti-
vated by allosteric regulation and suggest that this
mechanism is common for other initiator caspases.
Received July 12, 1999; revised version accepted November 1,
1999.
Caspases, a family of proteases, are a central part of the
apoptotic machinery (Thornberry and Lazebnik 1998).
Caspases are expressed as precursors that are activated in
a cascade following a pro-apoptotic stimulus. This cas-
cade begins with autocatalytic activation of initiator
caspases, which process and activate the effector
caspases that, in turn, disassemble a cell. Each initiator
caspase mediates a subset of pro-apoptotic signals.
Caspase-9 is required for normal brain development and
mediates apoptosis induced by chemotherapeutic drugs
and oncogenic transformation (Fearnhead et al. 1998;
Hakem et al. 1998; Kuida et al. 1998). As a consequence,
the loss of caspase-9 activity has been implicated in tu-
morigenesis (Soengas et al. 1999). Caspase-9 activation
requires binding of the precursor to a complex of two
proteins, APAF-1 and cytochrome c, and is dependent on
hydrolysis of dATP or ATP (Li et al. 1997; Hu et al. 1999;
Saleh et al. 1999; Zou et al. 1999). How formation of this
complex results in caspase-9 activation is not clear. A
current model (Muzio et al. 1998; Srinivasula et al. 1998;
Yang et al. 1998a,b; Saleh et al. 1999) argues that the
precursor of an initiator caspase has low activity that is
sufficient for autocatalytic processing but only when
two or more precursor molecules are brought into close
proximity by adaptor proteins, such as APAF-1. The pro-
cessed caspase becomes fully active and is free to cleave
its substrates. Previously we postulated an alternative
model in which proteins like APAF-1 facilitate autoca-
talysis of the caspase precursors by increasing their ac-
tivity through a conformational change (Thornberry and
Lazebnik 1998). The finding that the activity of recom-
binant caspase-9 increases in cell extracts suggested that
caspase activity can be changed by cytosolic factors
(Stennicke et al. 1999). Here we present evidence that
caspase-9 activity increases several orders of magnitude
when this caspase is in a complex with APAF-1. Hence,
these two proteins function as a holoenzyme in which
APAF-1 is an allosteric regulator of caspase-9.
Results and Discussion
Caspase-9 activation can be reproduced in a cell-free sys-
tem by incubating extracts from 293 cells with either
ATP or dATP (Liu et al. 1996; Fearnhead et al. 1998),
resulting in an “active extract”. In active extract, as in
cells, caspase-9 processes and activates caspase-3, a ma-
jor effector caspase. We found that the caspase-3 activity
increased linearly following addition of a nucleotide (Fig.
1A) until all caspase-3 was processed (Fig. 1B). The con-
stant rate of caspase-3 activation meant that caspase-9
activity had to be constant throughout the incubation.
Yet, the concentration of processed caspase-9, which is
thought to be the active form of the enzyme, increased
with time (Fig. 1C). This contradiction could be ex-
plained if not all processed caspase-9 is active. With this
in mind, we noticed that the amount of APAF-1 bound to
caspase-9 remained constant during the incubation (Fig.
1C,D). Moreover, this amount directly correlated with
the rate of caspase-3 activation (Fig. 1, ATP vs. dATP;
data not shown). Hence, the constant caspase-9 activity
could be explained if caspase-9 is active only in a com-
plex with APAF-1. A key condition for this hypothesis is
that processed caspase-9 remains bound to APAF-1. To
confirm that this complex is not an artifact of immuno-
precipitation, we fractionated the inactive and active ex-
tracts by sedimentation (Fig. 1E,F). We found that a frac-
tion of APAF-1 comigrated with processed caspase-9 as a
putative complex that was detected only in the active
extract. The size of the complex was similar to that re-
ported for recombinant proteins (Saleh et al. 1999; Zou et
al. 1999). All other caspases tested (3, 7, and 8) were not
detectable in this complex by immunoblotting, in con-
trast to the observations of others (Cain et al. 1999; Hu et
al. 1999).
To test our hypothesis directly, we decided to separate
free caspase-9 from the caspase-9–APAF-1 complex to
compare their activities. We first established a caspase-9
activity assay using caspase-3 precursor or its catalyti-
cally inactive mutant as substrates. In this assay,
caspase-9 immunoprecipitated from active extracts was
active, whereas caspase-9 immunoprecipitated from in-
active extracts or the mock precipitate from active ex-
tract was inactive (Fig. 2A,B). We then immunoprecipi-
tated all caspase-9 from the active extract, eluted it with
the epitope peptide, fractionated the eluate by sedimen-
tation, and measured the activity in each fraction. Al-
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though the complex contained only a minor fraction of
the total caspase-9 (Fig. 2C) it accounted for the majority
of the caspase-9 activity (Fig. 2D). The difference in rela-
tive activity was at least 1000-fold as estimated by com-
paring the caspase-9 activity and concentration (deter-
mined by densitometry of the caspase-9 immunoblot) in
the fractions. Similar results were obtained by doing this
experiment by first fractionating an active extract and
then measuring the activity of caspase-9 precipitated
from the fractions (Fig. 3B). These results were consis-
tent with the notion that caspase-9 is fully active only
when it is bound to APAF-1.
However, an alternative explanation could be that the
free caspase-9 is inactivated for reasons other than sepa-
ration from APAF-1. If our hypothesis is correct, free
caspase-9 should regain its activity if allowed to reform a
complex with APAF-1. One way of testing this is to add
free caspase-9 to an extract depleted of caspase-9.
Caspase-3 activation in this extract is abolished but
should be restored by adding functional caspase-9.
Caspase-9 precursor isolated from inactive extract res-
cued caspase-3 activation (Fig. 2E,G,I). As expected, the
activation was rescued only in the presence of dATP,
which is required for APAF-1 oligomerization (Fig. 2, cf.
G and I). Similarly, free processed caspase-9 rescued
caspase-3 activation and did it only in the presence of
dATP, indicating that the free caspase-9 is not irrevers-
ibly inhibited but requires the APAF-1 oligomer to re-
store its function (Fig. 2F,H,J). In contrast to free caspase-
9, the caspase-9–APAF-1 complex activated caspase-3
even without dATP, consistent with the notion that
dATP is required for caspase-9 activation but not for the
activity of the complex. Thus, these results indicated
that the processed caspase-9 is active only in a complex
with APAF-1, that is, caspase-9 and APAF-1 form a ho-
loenzyme in which caspase-9 is the catalytic and APAF-1
the regulatory subunit.
Considering how other proteases are regulated,
APAF-1 could increase caspase-9 activity by two mecha-
nisms. APAF-1 may provide an additional binding site
for caspase-3 (form a bridge), increase caspase-9 activity
through a conformational change (by allosteric regula-
tion), or both mechanisms could be involved. To evalu-
ate these possibilities we compared the activity of the
caspase-9 holoenzyme on caspase-3 and the peptide sub-
strate IETD-AFC (7amino-4-triflouromethylcoumarin)
which is derived from the caspase-9 cleavage site in
caspase-3. We reasoned that this peptide is too small to
Figure 1. The rate of caspase-3 activation correlates with the
amount of APAF-1 bound to caspase-9 (A,B) Caspases in 293
extract were activated by adding 5 mM ATP or dATP followed
by incubation at 37°C. At the indicated times, caspase-3 activ-
ity using DEVD-AFC as a substrate (A) and caspase-3 process-
ing, by immunoblotting with antibodies as indicated was as-
sayed (B). (C,D) At the indicated times aliquots of the extracts
were used to immunoprecipitate caspase-9. Caspase-9 (C) and
APAF-1 (D) in the precipitate were detected by immunoblot-
ting. (E,F) A fraction of processed caspase-9 is in a putative com-
plex with APAF-1 (star in F). A total of 50 µl (1.5 mg) of 293
extract was supplemented with 5 mM dATP and incubated at
37°C for 8 min (active extract). A control aliquot was incubated
with buffer (inactive extract). Both aliquots were fractionated on
5 ml of 5%–20% linear sucrose gradients and the fractions were
analyzed by immunoblotting for APAF-1, caspase-9, and cyto-
chrome c. Sedimentation markers have been described.
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bind simultaneously to the catalytic site of caspase-9 and
an additional site on APAF-1. Thus, if both free caspase-9
and the holoenzyme cleave the peptide at the same rate,
but only holoenzyme cleaves caspase-3, then APAF-1
provides a bridge. If both the peptide and caspase-3 are
cleaved preferentially by the holoenzyme, then APAF-1
allosterically regulates caspase-9. With both substrates,
the activity of the holoenzyme was greater than that of
free caspase-9, consistent with the model that APAF-1
increases the catalytic activity of caspase-9 by allosteric
regulation. Because free caspase-9 did cleave IETD-AFC,
although at a lower rate than the holoenzyme, but did
not process caspase-3, APAF-1 may also have some
bridging effect. An intrinsic caveat of this experiment is
that in principle an activity other than that of caspase-9
could copurify with the holoenzyme and be responsible
for cleavage of IETD-afc.
We isolated the caspase-9 holoenzyme from cells that
overexpressed catalytically inactive caspase-9, we used
this approach to obtain amounts of the complex large
enough to obtain protein sequence of unknown compo-
nents should there be any. However, the only proteins
detected were APAF-1 and caspase-9 (Fig. 3D). This does
not rule out the possibility that weakly associated or
labile proteins regulate the caspase-9 holoenzyme. More-
over, factors other than polypeptides may be involved, as
in blood clotting where not only cofactor Va but also
calcium and phospholipids are cofactors for the protease
factor Xa. Cytochrome c is required for caspase-9 activa-
tion and was a part of the recombinant caspase-9–
APAF-1 complex (Zou et al. 1999). We failed to detect
cytochrome c in the holoenzyme not only by Coomassie
staining but also by immunoblotting (Fig. 1E,F). This can
be explained either by inadequate detection techniques
or by the lack of cytochrome c in the holoenzyme. The
role of cytochrome c may be limited to APAF-1 oligo-
merization and once APAF-1 oligomer is formed, cyto-
chrome c may not be required for caspase-9 binding and
activation.
Having established that caspase-9 is active as a holo-
enzyme in a cell-free system, we investigated which
form of caspase-9 is active in apoptotic cells. We used
extracts from IMR90-E1A cells (human fibroblasts trans-
formed with adenoviral oncogene E1A (Fearnhead et al.
1998) that were treated with the chemotherapeutic drug
etoposide. Extracts from untreated cells were used as a
control. Caspase-9 precipitated from extracts of apop-
totic cells processed caspase-3, whereas caspase-9 pre-
cipitated from control extracts did not (Fig. 4A). We then
fractionated extracts by sedimentation, immunoprecipi-
tated caspase-9 and measured its activity. As in the cell-
free system, caspase-9 activity was greater in the frac-
tions corresponding to the holoenzyme (Fig. 4D). How-
ever, we did not detect a distinct caspase-9–APAF-1
complex by immunoblotting (Fig. 4C), perhaps due to the
low synchrony of apoptosis in cell populations or the low
solubility of the complex in cells.
The finding that APAF-1 increases caspase-9 activity,
Figure 2. Caspase-9 is active only in a complex with APAF-1.
(A) Caspase-9 depleted from active extracts can activate
caspase-3. Caspase-9 was depleted from active or inactive ex-
tracts eluted with the epitope peptide, and its activity was ana-
lyzed using caspase-3 precursor as a substrate. Sepharose with
no antibody bound was used for mock depletions. (B) Caspase-9
depleted from active extracts can process catalytically inactive
caspase-3. The experiment was done as in A, but the caspase-3
used was made inactive by mutating the catalytic Cys-163 to
serine. (C,D) Caspase-9 was depleted from 4 ml (~ 135 mg) active
extract as in A and fractionated, analyzed for APAF-1 and
caspase-9 by immunoblotting (C) and for caspase-9 activity (D)
using caspase-3 as in B (1-hr incubation). APAF-1 and caspase-9
in fraction 17 (the bottom of the gradient) are likely to be an
aggregate formed by anti-caspase-9 antibodies that leached from
Sepharose and were detected only in this fraction (not shown).
(E,F) Both free processed caspase-9 and the caspase-9 holoen-
zyme can rescue caspase-3 activation in extracts depleted of
caspase-9. A total of 240 µl (6.4 mg) of active or inactive extracts
was fractionated by sedimentation in sucrose gradients and
caspase-9 was immunoprecipitated from each fraction and
eluted with the epitope peptide. The amounts of caspase-9 and
APAF-1 that coprecipitated with caspase-9 from the active ex-
tract were estimated in the eluates by immunoblotting (E,F).
The eluates were added to aliquots of inactive extract that was
immunodepleted of caspase-9. The aliquots were then incu-
bated for 15 min at 37°C either with buffer (G,H) or dATP (I,J)
and caspase-3 activity was measured with DEVD–AFC as a sub-
strate.
Caspase-9 holoenzyme
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and the observations that autocatalytic cleavage of
caspase-9 is intramolecular (Zou et al. 1999) and that a
recombinant caspase-9 mutated at the processing sites
has partial activity in a cell-free system (Stennicke et al.
1999), suggest the following model for caspase-9 activa-
tion (Fig. 4E). A pro-apoptotic agent induces release of
cytochrome c. Binding of cytochrome c to APAF-1 re-
sults in the nucleotide-dependent formation of an
APAF-1 oligomer (Zou et al. 1999). This oligomer, but
not free APAF-1, binds to caspase-9 and increases its ac-
tivity through allosteric interaction. This activity is suf-
ficient to carry out intramolecular processing resulting
in fully active caspase-9. The APAF-1-bound and free
caspase-9 remain in a steady-state equilibrium in which
only the bound form is active.
Regulation of protease activity is
hardly a new concept. For example, tis-
sue factor initiates the blood clotting
cascade by binding and allosterically ac-
tivating factors VII and VIIa (Jesty and
Nemerson 1995). The adenoviral prote-
ase (AVP) is activated by the stepwise
binding to two cofactors, the viral DNA
and to a peptide excised from a viral pro-
tein by the AVP–DNA complex (Mangel
et al. 1997). The increase in protease ac-
tivity by cofactors can range from sever-
alfold to 1 million (Mann et al. 1992).
The mechanism of allosteric regulation
is demonstrated most convincingly by
solving the structure of the protein com-
plex and the free components. The struc-
ture of the complex between the
caspase-9 and APAF-1 caspase recruit-
ment domains (CARDs) is an important
step in this direction (Qin et al. 1999).
Considering how other protease precur-
sors are activated (Khan and James 1998),
a reasonable hypothesis is that APAF-1
removes the caspase-9 prodomain from
its catalytic site.
What are the implications of caspase-9
being active as a holoenzyme? A practi-
cal implication is that in vitro screens
for caspase-9 substrates and inhibitors,
including potential therapeutics, should
use the caspase-9 holoenzyme rather
than caspase-9 alone. Another is that
caspase-9 activity may be regulated even
after caspase-9 processing, for example,
by sequestering caspase-9 from the holo-
enzyme. Also, the activity of caspase-9
in a cell can be limited by the amount of
APAF-1 oligomer. As a consequence, a
catalytically inactive caspase-9 should
be a competitive inhibitor of caspase-9
activity even if all caspase-9 in the cell is
processed. This is consistent with the
otherwise difficult to explain high effi-
ciency of caspase-9 dominant-negative
mutant and caspase-9 “decoys” as inhibitors of apoptosis
(Fearnhead et al. 1998; Srinivasula et al. 1998, 1999; Seol
and Billiar 1999). The proposed mechanism would also
mean that a mutant caspase-9 may inhibit apoptosis
even if expressed only by one allele in a tumor cell. Al-
though caspase-9 mutations in tumors have not yet been
reported, a missense mutation in one allele of the
caspase-10 gene can cause apoptotic defects underlying
autoimmune lymphoproliferative syndrome (ALPS) type
II (Wang et al. 1999).
Oncogenes sensitize cells to apoptosis by facilitating
the activation of caspase-9, and this facilitation is not
restricted to cytochrome c release (Fearnhead et al. 1998;
Juin, et al. 1999). We suggest that oncogenic transforma-
tion regulates the subsequent steps of caspase-9 activa-
Figure 3. (A–C) Binding to APAF-1 increases the catalytic activity of caspase-9. A
total of 1.5 ml (60 mg) of active extract was fractionated by sedimentation. Each
fraction was divided into two aliquots, one of which was immunoprecipitated with
anti-caspase-9–Sepharose, and the other mock precipitated with Sepharose. Both pre-
cipitates were eluted with the epitope peptide. (A) The amount of caspase-9 and
APAF-1 in the anti-caspase-9–Sepharose eluate as revealed by immunoblotting. The
activity of the eluates [(solid bars) anti-caspase-9, (open bars) mock] was measured
using either caspase-3 precursor (B) or a IETD–AFC peptide substrate (C). The open
bars in B are not seen because the activity of the mock precipitates was low. (D) The
main components of the holoenzyme are APAF-1 and caspase-9. Catalytically inac-
tive caspase-9 containing the Flag epitope tag was stably expressed in 293 cells. A
total of 500 µl (20 mg) of extract from these cells was incubated with 1 mM dATP at
37°C for 10 min, and caspase-9 was precipitated using anti-Flag antibodies linked to
agarose (Sigma). An equal amount of extract from parental 293 cells was treated
identically and used for a control precipitation. The precipitates from both extracts
were fractionated on a 10% or 15% (not shown) SDS–polyacrylamide gel, which was
then stained with Coomassie blue. Caspase-9 and APAF-1 were identified by immu-
noblotting and immunoprecipitation (data not shown).
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tion, such as the formation of the caspase-9 holoenzyme
or its activity, perhaps by regulating the concentration of
the APAF-1 oligomer.
Considering structural similarities among initiator
caspases and among the adaptor proteins (e.g., CED-4,
APAF-1, and putative APAF-1 homolog FLASH (Zou et
al. 1997; Imai et al. 1999) we speculate that initiator
caspases other than caspase-9 are also activated alloste-
rically and function as holoenzymes. The mechanism of
induced activity may also apply to the caspases that are
involved in processes other than apoptosis.
Materials and methods
Antibodies
The monoclonal antibodies to caspase-9 (1-2), caspase-3 (4-1-18), and
APAF-1 (1-19) were described previously (Fearnhead et al. 1998). Anti-
body to cytochrome c was provided by Dr. Jemmerson (University of
Minnesota Medical School, Minneapolis).
Assay for caspase-9 activity
Caspase-3 as a substrate
An aliquot of caspase-9 was supplemented with recombinant caspase-3
precursor to the final concentration of 400 nM and incubated at 37°C for
the times indicated in the legends to figures 1–4. Three-microliter ali-
quots of the reactions were then added to 200 µl of caspase-3 assay buffer
(40 µM DEVD-AFC in 10 mM HEPES, 0.5 mM EGTA, 10% glycerol at pH
7.0), and the rate of DEVD cleavage was measured with a fluorescence
plate reader (Cytofluor, Perseptive Biosystems) and presented as arbitrary
fluorescence units per minute (FU/min); 1 FU is equivalent to 0.65 pmole
released AFC.
IETD-AFC as a substrate
An aliquot of 440 µM IETD-AFC was added directly to the eluates to a
final concentration of 40 µM and incubated for 9 hr at 37°C. The increase
in fluorescence was measured with the fluorescence plate reader and
presented in arbitrary fluorescence units.
Immunoprecipitation and sedimentation in sucrose gradients
Extracts or extract fractions were incubated for 2 hr at 4°C with CNBr–
Sepharose beads cross-linked to caspase-9 mAb 1-2 (3 mg/ml) that was
affinity purified on caspase-9-Sepharose. A total of 10 µl of beads was
used per 1 ml (~ 25 mg) of extract or per a 300-µl fraction. The beads were
washed three times with NPM (50 mM PIPES, 50 mM NaCl, 5 mM EGTA,
1 mM MgCl, 5 mM DTT at pH 7.0) supplemented with 5% sucrose. Bound
caspase-9 was eluted for 2 hr at 4°C with 200 µg/ml epitope peptide in
NPM supplemented with 1 mg/ml BSA and 5% sucrose.
Cell extract (5 mg in 150 µl) or immunoprecipitate was loaded onto a
5-ml tube containing 5%–20% sucrose gradient in NMP and sedimented
at 4°C for 5 hr (100,000g) at 36,000 rpm. Fractions (300-µl) were collected
from the top. BSA (4.5S, 66 kD), catalase (11.3S, 240 kD) and thyroglob-
Figure 4. Caspase-9 is active in cells as a holoenzyme. Human fibroblasts transformed with the adenoviral E1A oncogene (IMR90-
E1A) were either treated with 50 µM etoposide for 18 hr (sixteen 15-cm plates) or left untreated (8 plates) and used to prepare extracts
(Liu et al. 1996). (A) Only caspase-9 from treated cells is active. Caspase-9 was precipitated from the extracts and assayed for activity
using caspase-3. (B,C) A total of 600 µl (9 mg) of each extract was fractionated by sedimentation in sucrose gradients, and the amount
of caspase-9 and APAF-1 in the fractions evaluated by immunoblotting. (D) Caspase-9 was immunoprecipitated from the fractions,
eluted with the epitope peptide, and the activity was measured as in A (14 hr incubation). (E) A model for caspase-9 activation and
activity.
Caspase-9 holoenzyme
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ulin (19.4S, 669 kD) were used as sedimentation markers. Several tubes
were used to fractionate larger amounts of extract, and the fractions from
each tube were combined.
Expression and purification of caspase-3 precursor
Caspase-3 precursor and its catalytically inactive mutant, both contain-
ing the amino-terminal His6 tag, were expressed in Escherichia coli from
the pQE30 vector (Qiagen) and purified by chromatography on Ni-aga-
rose.
Cell lines
293 cells expressing catalytically inactive caspase-9 were obtained using
the Marx IV retroviral expression system (kind gift of Dr. Greg Hannon,
Cold Spring Harbor Laboratory).
Acknowledgments
We thank Ximena Opitz-Araya for excellent technical help; Ryuji Ko-
bayashi and Nora Poppito for helping to map the antibody epitope; Jeanne
Wiggins for massive cell culture; Jonathan Hoffman (Harborfields High
School) for extract preparation; and Tatsuya Hirano, Arne Stenlund, and
Adrian Krainer for helpful discussion. J.R. is a Howard Hughes Medical
Institute predoctoral fellow. Y.L. is a Pew Scholar. This work was sup-
ported by National Institutes of Health grant CA 13106-25 to Y.L.
The publication costs of this article were defrayed in part by payment
of page charges. This article must therefore be hereby marked “adver-
tisement” in accordance with 18 USC section 1734 solely to indicate this
fact.
References
Cain, K., D.G. Brown, C. Langlais, and G.M. Cohen. 1999. Caspase acti-
vation involves the formation of the aposome, a large (approximately
700 kDa) caspase-activating complex. J. Biol. Chem. 274: 22686–
22692.
Fearnhead, H.O., J. Rodriguez, E.E. Govek, W. Guo, R. Kobayashi, G.
Hannon, and Y.A. Lazebnik. 1998. Oncogene-dependent apoptosis is
mediated by caspase-9. Proc. Natl. Acad. Sci. 95: 13664–13669.
Hakem, R., A. Hakem, G.S. Duncan, J.T. Henderson, M. Woo, M.S. So-
engas, A. Elia, J.L. de la Pompa, D. Kagi, W. Khoo et al. 1998. Differ-
ential requirement for caspase 9 in apoptotic pathways in vivo. Cell
94: 339–352.
Hu, Y., M. Benedict, L. Ding, and G. Nunez. 1999. Role of cytochrome c
and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation
and apoptosis. EMBO J. 18: 3586–3595.
Imai, Y., T. Kimura, A. Murakami, N. Yajima, K. Sakamaki, and S. Yone-
hara. 1999. The CED-4 homologous protein FLASH is involved in
Fas-mediated activation of caspase-8 during apoptosis. Nature 398:
777–785.
Jesty, J. and Y. Nemerson. 1995 The pathway of blood coagulation. In
Williams hematology (eds. E. Beutker, M.A. Lichtman, B.S. Coller,
and T.J. Kipps) pp. 1227–1238. McGraw-Hill, New York, NY.
Juin, P., A.O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-induced
sensitization to apoptosis is mediated through cytochrome c release.
Genes & Dev. 13: 1367–1381.
Khan, A. and M. James. 1998. Molecular mechanisms for the conversion
of zymogens to active proteolytic enzymes. Protein Sci. 7: 815–836.
Kuida, K., T.F. Haydar, C.Y. Kuan, Y. Gu, C. Taya, H. Karasuyama, M.S.
Su, P. Rakic, and R.A. Flavell. 1998. Reduced apoptosis and cyto-
chrome c-mediated caspase activation in mice lacking caspase 9. Cell
94: 325–337.
Li, P., D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S.
Alnemri, and X.D. Wang. 1997. Cytochrome c and dATP-dependent
formation of Apaf-1/caspase-9 complex initiates an apoptotic prote-
ase cascade. Cell 91: 479–489.
Liu, X., C.N. Kim, J. Yang, R. Jemmerson, and X. Wang. 1996. Induction
of apoptotic program in cell-free extracts: requirement for dATP and
cytochrome c. Cell 86: 147–157.
Mangel, W.F., D.L. Toledo, J.Z. Ding, R.M. Sweet, and W.J. McGrath.
1997. Temporal and spatial control of the adenovirus proteinase by
both a peptide and the viral DNA. Trends Biochem. Sci. 22: 393–398.
Mann, K., S. Krishnaswamy, and J. Lawson. 1992. Surface-dependent he-
mostasis. Semin. Hematol. 29: 213–226.
Muzio, M., B.R. Stockwell, H.R. Stennicke, G.S. Salvesen, and V.M.
Dixit. 1998. An induced proximity model for caspase-8 activation. J.
Biol. Chem. 273: 2926–2930.
Qin, H., S.M. Srinivasula, G. Wu, T. Fernandes-Alnemri, E.S. Alnemri,
and Y. Shi. 1999. Structural basis of procaspase-9 recruitment by the
apoptotic protease-activating factor 1. Nature 399: 549–557.
Saleh, A., S.M. Srinivasula, S. Acharya, R. Fishel, and E.S. Alnemri. 1999.
Cytochrome c and dATP-mediated oligomerization of apaf-1 is a pre-
requisite for procaspase-9 activation. J. Biol. Chem. 274: 17941–
17945.
Seol, D.W. and T.R. Billiar. 1999. A caspase-9 variant missing the cata-
lytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem. 274:
2072–2076.
Soengas, M.S., R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem, T.W.
Mak, and S.W. Lowe. 1999. Apaf-1 and caspase-9 in p53-dependent
apoptosis and tumor inhibition. Science 284: 156–159.
Srinivasula, S.M., M. Ahmad, T. Fernandes-Alnemri, and E.S. Alnemri.
1998. Autoactivation of procaspase-9 by Apaf-1-mediated oligomer-
ization. Mol. Cell 1: 949–957.
Srinivasula, S.M., M. Ahmad, Y. Guo, Y. Zhan, Y. Lazebnik, T. Fer-
nandes-Alnemri, and E.S. Alnemri. 1999. Identification of an endog-
enous dominant-negative short isoform of caspase-9 that can regulate
apoptosis. Cancer Res. 59: 999–1002.
Stennicke, H.R., Q.L. Deveraux, E.W. Humke, J.C. Reed, V.M. Dixit, and
G.S. Salvesen. 1999. Caspase-9 can be activated without proteolytic
processing. J. Biol. Chem. 274: 8359–8362.
Thornberry, N.A. and Y. Lazebnik. 1998. Caspases: enemies within. Sci-
ence 281: 1312–1316.
Wang, J., L. Zheng, A. Lobito, F. Chan, K. Dale, M. Sneller, X. Yao, J.
Puck, S. Straus, and M. Lenardo. 1999. Inherited human caspase 10
mutations underlie defective lymphocyte and dendritic cell apoptosis
in autoimmune lymphoproliferative syndrome type II. Cell 98: 47–
58.
Yang, X., H.Y. Chang, and D. Baltimore. 1998a. Essential role of CED-4
oligomerization in CED-3 activation and apoptosis. Science 281:
1355–1357.
———. 1998b. Autoproteolytic activation of pro-caspases by oligomer-
ization. Mol. Cell 1: 319–325.
Zou, H., W.J. Henzel, X. Liu, A. Lutschg, and X. Wang. 1997. Apaf-1, a
human protein homologous to C. elegans CED-4, participates in cy-
tochrome c-dependent activation of caspase-3. Cell 90: 405–413.
Zou, H., Y. Li, X. Liu and X. Wang. 1999. An APAF-1.Cytochrome c
multimeric complex is a functional apoptosome that activates pro-
caspase-9. J. Biol. Chem. 274: 11549–11556.
Rodriguez and Lazebnik
3184 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on December 12, 2012 - Published by genesdev.cshlp.orgDownloaded from 
